The NDV-MLS as an Immunotherapeutic Strategy for Breast Cancer: Proof of Concept in Female Companion Dogs with Spontaneous Mammary Cancer
Viruses · 2024
DOI: 10.3390/v16030372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Diana Sánchez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Mexico City 14080, Mexico. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Nacional de Cancerología, Mexico.
Abstract (Originalsprache)
The absence of tumor-infiltrating lymphocytes negatively impacts the response to chemotherapy and prognosis in all subtypes of breast cancer. Therapies that stimulate a proinflammatory environment may help improve the response to standard treatments and also to immunotherapies such as checkpoint inhibitors. Newcastle disease virus (NDV) shows oncolytic activity, as well as immune modulating potential, in the treatment of breast cancer in vitro and in vivo; however, its potential to enhance tumor-infiltrating immune cells in breast cancer has yet to be evaluated. Since spontaneous canine mammary tumors represent a translational model of human breast cancer, we conducted this proof-of-concept study, which could provide a rationale for further investigating NDV-MLS as immunotherapy for mammary cancer. Six female companion dogs with spontaneous mammary cancer received a single intravenous and intratumoral injection of oncolytic NDV-MLS. Immune cell infiltrates were evaluated by histology and immunohistochemistry in the stromal, intratumoral, and peritumoral compartments on day 6 after viral administration. Increasing numbers of immune cells were documented post-viral treatment, mainly in the peritumoral compartment, where plasma cells and CD3+ and CD3-/CD79- lymphocytes predominated. Viral administration was well tolerated, with no significant adverse events. These findings support additional research on the use of NDV-MLS immunotherapy for mammary cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
- Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
- NorthStar VETS, Veterinary Emergency Trauma & Specialty Centers, Robbinsville, NJ 08691, USA.
- Departamento de Hematología, Instituto Nacional de Cancerología, Mexico City 14080, Mexico.
- Departamento de Patología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
- Departamento de Patología, Hospital Ángeles Pedregal, Mexico City 10700, Mexico.
ORCID-Profile: Gabriela Cesarman-Maus, Rosa Elena Sarmiento-Silva, Marcela Lizano
Förderung
- Instituto Nacional de Cancerología, Mexico
Zitieren
APA
Sánchez, D., Cesarman-Maus, G., Romero, L., Sánchez-Verin, R., Vail, D., Guadarrama, M., Pelayo, R., Sarmiento-Silva, R. E., & Lizano, M. (2024). The NDV-MLS as an Immunotherapeutic Strategy for Breast Cancer: Proof of Concept in Female Companion Dogs with Spontaneous Mammary Cancer. Viruses. https://doi.org/10.3390/v16030372
Vancouver
Sánchez D, Cesarman-Maus G, Romero L, Sánchez-Verin R, Vail D, Guadarrama M, et al. The NDV-MLS as an Immunotherapeutic Strategy for Breast Cancer: Proof of Concept in Female Companion Dogs with Spontaneous Mammary Cancer. Viruses. 2024. doi:10.3390/v16030372
BibTeX
@article{Snchez2024,
author = {Sánchez, Diana and Cesarman-Maus, Gabriela and Romero, Laura and Sánchez-Verin, Rogelio and Vail, David and Guadarrama, Marina and Pelayo, Rosana and Sarmiento-Silva, Rosa Elena and Lizano, Marcela},
title = {The NDV-MLS as an Immunotherapeutic Strategy for Breast Cancer: Proof of Concept in Female Companion Dogs with Spontaneous Mammary Cancer},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16030372}
}
EUVIMED